What is less discussed is that targeted sleep peptide therapy may offer a biological lever to break that cycle not by forcing sedation, but by restoring the hormonal architecture of recovery
The observed increase in mitochondrial malate and cytosolic 2-oxoglutarate through elevated SLC25A11 expression aligns with the systemic energetic dysregulation and oxidative stress reported in plasma metabolomic studies in ME/CFS patients
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinsons disease: mechanisms of action
Weight Loss Both semaglutide and liraglutide work by activating GLP-1 receptors in the brain, which helps to: Suppress appetite Increase satiety Decrease caloric intake Increase thermogenesis In clinical studies, individuals with obesity or overweight who took either medication experienced significant reductions in body weight compared to those who received a placebo [2, 10]
Statements Author contributions EK, SS, and SMN conceived the idea, collected the papers, and wrote the manuscript